Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 438 Publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 M2G0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[0JIQ> MXvJR|UxRTVwN{C1JEDPxE1i NXHxTVRsOTh3NUm2NVM>
KP6.3 NEfjO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljZOEBl MYTJR|UxRTFyLkSyPEDPxE1i Mn\2NVg2PTl4MUO=
KP7.7 Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW[0JIQ> NGPMXpNKSzVyPUW3JI5OKA>? NVjDSWJlOTh3NUm2NVM>
KB2P3.4 M{TLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTxOEBl MVvJR|UxRTF{NDDNJC=> NWjLOWRMOTh3NUm2NVM>
KB2P1.21 NUixeWl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[3T4VXPCCm NYnke2tlUUN3ME24PVA4KG6PIB?= NV\FTmE2OTh3NUm2NVM>
U373-MG MnjMR5l1d3SxeHnjJGF{e2G7 NU\0XWJ3OSEQvF2g M4\oPFI1KGh? NXTySHR5UW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= NWS3SZdIOTh7NUS3NVI>
T98G Moi2R5l1d3SxeHnjJGF{e2G7 MlHZNUDPxE1i NIjOU3MzPCCq NHrSV|lKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 MkHXNVg6PTR5MUK=
U87-MG NFy1XphEgXSxdH;4bYMhSXO|YYm= M{PIRVEh|ryPIB?= MlTnNlQhcA>? NICzZZhKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NHz0e3oyQDl3NEexNi=>
UVW NHWyW3ZEgXSxdH;4bYMhSXO|YYm= MojyOVAxKG6P NGToT3MzPCCq NUnZN29oUW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= NVTGWVBKOTh7NUS3NVI>
HeLa MV7GeY5kfGmxbjDBd5NigQ>? NUWxbZpRPTByIH7N M{fjVFQhcA>? NVjDTVRHS2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu| MYSxPFk2PDdzMh?=
HeLa NIfr[GpHfW6ldHnvckBCe3OjeR?= NHTmWYcyKM7:TTC= M3nQT|I1KGh? NHjzcWFGdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBUNXCqYYPlJIFzemW|dB?= MlX6NVg6PTR5MUK=
T98G MnfjSpVv[3Srb36gRZN{[Xl? MkixNUDPxE1i NYfabnFUOjRiaB?= NYHyT|hnTW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S= MV[xPFk2PDdzMh?=
L3 MV\DfZRwfG:6aXOgRZN{[Xl? NF\Xb3g2KM7:TTC= NFK0cHI6PiCq NVHC[oZZTE2VTx?= MWLTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy= NYfMOFlbOjBzMkS0OVk>
Granta-519 MnfJR5l1d3SxeHnjJGF{e2G7 MoXpOUDPxE1i MkPBPVYhcA>? MWXEUXNQ MXjTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NH;iXoszODF{NES1PS=>
BT MoS0R5l1d3SxeHnjJGF{e2G7 Mk\pOUDPxE1i NYHnNmczQTZiaB?= M2m3VmROW09? NHu3VlFUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu MlXTNlAyOjR2NUm=
UPN2 Ml3YR5l1d3SxeHnjJGF{e2G7 M3fldlUh|ryPIB?= NGPUOW06PiCq M3;HSGROW09? MW\TcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MkfYNlAyOjR2NUm=
HBL-2 NFPFeIlEgXSxdH;4bYMhSXO|YYm= NUW3cWxCPSEQvF2g MVq5OkBp NIPsTotFVVOR NX\QcGd1W2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= M3rOVVIxOTJ2NEW5
JVM-2 MlvsR5l1d3SxeHnjJGF{e2G7 M3\0PVUh|ryPIB?= Mn3NPVYhcA>? NVTKVppYTE2VTx?= M{\ZUXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx? NVfLdHo2OjBzMkS0OVk>
Z138 NFjBWVhEgXSxdH;4bYMhSXO|YYm= Mn[4OUDPxE1i MY[5OkBp M3\UU2ROW09? Mn7PV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? MmfnNlAyOjR2NUm=
RWPE NILG[2tKdn[jc3n2[UBCe3OjeR?= MkKzNlUh|ryP NEflTJQ1QCCq MkS0SG1UVw>? M1KxSXNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> Mnj6NlE2PzV6NkW=
VCaP MXjJcpZie2m4ZTDBd5NigQ>? MUiyOUDPxE1? MXy0PEBp NHvrWnJFVVOR M1XOXHNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> MWCyNVU4PTh4NR?=
Mouse H2AX−/− ES Cells M1H6bGN6fG:2b4jpZ{BCe3OjeR?= MYKyMlUh|ryP NFLLbYMzOCCq MnXZV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs MX:yN|M2PTR6OR?=
Mouse ATM−/− ES Cells M1TZc2N6fG:2b4jpZ{BCe3OjeR?= MXGyMlUh|ryP NF7BSGIzOCCq NEfIWoxUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> MlPJNlM{PTV2OEm=
H1650 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[yNEDPxE1? NXrlV4F1OTR2IHi= Mk[xTWM2OD1zNT60O{DPxE1? MmDCNlMzOzl6MEm=
H1650PTEN+ MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfUWmg1OjBizszN NHfvUGIyPDRiaB?= M3f1fGlEPTB;NUCuPFMh|ryP NFvGVoczOzJ|OUiwPS=>
PC-9 NWW3coRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfiVYgzOCEQvF2= MX[xOFQhcA>? NXrsXIpkUUN3ME21Mlg5KM7:TR?= M4LIPFI{OjN7OEC5
PC-9PTEN− M3PuZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDidVUzOCEQvF2= MkLrNVQ1KGh? NH7rcpZKSzVyPU[uOVIh|ryP NFvJVoozOzJ|OUiwPS=>
MDA-MB-231 M3foXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfWZ2o2KGSjeR?= NHr1dJdKSzVyPU[uPUDPxE1? NGXjPVkzOzd4MES5Oi=>
MDA-MB-468 NGHFVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTyeVhnPSCmYYm= MWjJR|UxRTVwMDFOwG0> M4DlO|I{PzZyNEm2
BT20 NULiUm9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\zbYhlPSCmYYm= MoDMTWM2OD15Lkeg{txO MXGyN|c3ODR7Nh?=
HCC1143 NV7L[opsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXteow2KGSjeR?= M2f1W2lEPTB;MUGuNUDPxE1? NHLpTGEzOzd4MES5Oi=>
HCC1937 NXr5UGJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7vfVY2KGSjeR?= MWrJR|UxRTF{Lk[g{txO MXqyN|c3ODR7Nh?=
Hs578t M33icWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT4d242KGSjeR?= MYXJR|UxRTVwNjFOwG0> NGGxO44zOzd4MES5Oi=>
Hs578t(si) NYTE[Vc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjpWos2KGSjeR?= MX7JR|UxRTdwNTFOwG0> NVHGcpdvOjN5NkC0PVY>
BT474 MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq1PVM2KGSjeR?= MmrqTWM2OD1zOT64JO69VQ>? MXWyN|c3ODR7Nh?=
JIMT1 NGP5TmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13GTlUh\GG7 NUnyOo5GUUN3ME23Mlch|ryP NV;rdFdsOjN5NkC0PVY>
SKBR3 MnzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjL[GI2KGSjeR?= MWDJR|UxRTFzLkGg{txO M2LsVlI{PzZyNEm2
SUM159 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPEOUBl[Xl? NUfhbHRLUUN3ME20MlIh|ryP NF\XdGozOzd4MES5Oi=>
CAMA1 NGGwRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFe1S3E2KGSjeR?= NHi3S45KSzVyPUG1Mlgh|ryP MkD5NlM4PjB2OU[=
MCF7 NWjud2diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLCdlA2KGSjeR?= NX[xfXBnUUN3ME21Mlgh|ryP NEDFeXozOzd4MES5Oi=>
T47D NH2w[VJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYK1JIRigQ>? M2C4bWlEPTB;OT62JO69VQ>? NELifWszOzd4MES5Oi=>
HCT116 M4TqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XnUlExOCEQvF2= M{THR|Q5KGh? NYTXUnEzTE2VTx?= M4TyTGlEPTB;Mj61JO69VSB? Mn3wNlQ2Pzd7NEG=
SW1116 Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfIOWtuOTByIN88US=> NU\kOnRvPDhiaB?= MXTEUXNQ NEG0W5pKSzVyPUGwNEDPxE1? M{nreVI1PTd5OUSx
HT29 MkTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n6T|ExOCEQvF2= M3HES|Q5KGh? MXjEUXNQ NYTafnU4UUN3ME2xOE44KM7:TR?= M2H6dFI1PTd5OUSx
LoVo MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorMNVAxKM7:TR?= MUe0PEBp MVPEUXNQ MnfiTWM2OD1zMz60JO69VQ>? NHPZfmkzPDV5N{m0NS=>
HCT-15 NXnhU25mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYraUldIOTByIN88US=> MXS0PEBp MmexSG1UVw>? M2jYVmlEPTB;MUCg{txO MV[yOFU4Pzl2MR?=
SW48 NYnDbWhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TRNFExOCEQvF2= NVH1OI5yPDhiaB?= MlPQSG1UVw>? NFfCZ5RKSzVyPUmuOUDPxE1? MlLqNlQ2Pzd7NEG=
C-1 NX[1NnhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\qfXEyODBizszN NH63PFA1QCCq M2\xXmROW09? NYq2bm54UUN3ME23MlYh|ryP M{\icFI1PTd5OUSx
RKO M3LxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fSSlExOCEQvF2= NGPtOVQ1QCCq Mm\3SG1UVw>? MmLXTWM2OD13Lkmg{txO NVfYNoVmOjR3N{e5OFE>
HCT116 NEjDbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7wNVAxKM7:TR?= MWG0PEBp MkXrSG1UVw>? NWLpfG92WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NVz1NZJTOjR3N{e5OFE>
SW1116 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW3NVAxKM7:TR?= MVq0PEBp NU\4Oo5HTE2VTx?= NGHBNY5Rd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli M{X1cVI1PTd5OUSx
HT29 NInwcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWxNFAh|ryP M1rpUFQ5KGh? Ml[5SG1UVw>? NYHic5RjWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NHXjZoczPDV5N{m0NS=>
LoVo NUXpdY9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TZclExOCEQvF2= NFfFRW01QCCq NELNe4JFVVOR MXjQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkh MmPjNlQ2Pzd7NEG=
SW48 NGjtVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknENVAxKM7:TR?= M{THclQ5KGh? NWfDTIdsTE2VTx?= NVnMPIRpWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NXSxWFBEOjR3N{e5OFE>
C-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnPWWIyODBizszN MVW0PEBp M4[xO2ROW09? M3vCW3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NFHKcW4zPDV5N{m0NS=>
RKO NVv1dIk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\3NVAxKM7:TR?= MnmyOFghcA>? NUjTN2NyTE2VTx?= M3fOW3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NV3aNplmOjR3N{e5OFE>
HCT116 M4fpT2Z2dmO2aX;uJGF{e2G7 NETPWmkyOCCwTR?= NF31fWoyOiCq MXLEUXNQ NFnWdm9KdmO{ZXHz[ZMhTE6DIHTveYJt\S2|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i= NUXyN3VDOjR3N{e5OFE>
HT29 M3j6eGZ2dmO2aX;uJGF{e2G7 Mk\4NVAhdk1? MojtNVIhcA>? MVHEUXNQ MWHJcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? M2D2fFI1PTd5OUSx
TE-6 MUHGeY5kfGmxbjDBd5NigQ>? NVvP[GdMPSEQvF2g NGP5VFcyOiCq M2TNS2ROW09? NVvzRW5XUW6mdXPld{BIOi:PIHHydoV{fA>? MnXpNlQzOTlzNkS=
TE-6 NHq1OHVHfW6ldHnvckBCe3OjeR?= Ml;XOUDPxE1i M2TFW|I1KGh? MVvEUXNQ MX\JcoNz\WG|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq M2nZOVI1OjF7MU[0
Hep3B NIPYfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGwOFAh|ryPIB?= NIrpRYo4OiCq MlzlSG1UVw>? NVPxWFJKW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF? MViyOVA4Ojd3Mh?=
Huh7 M1vrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfyOFAh|ryPIB?= NW\DXGNiPzJiaB?= MlL3SG1UVw>? MWHTfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=> Mk\KNlUxPzJ5NUK=
Hep3B MofvSpVv[3Srb36gRZN{[Xl? MmfJOFAh|ryPIB?= NVXJPWNpOjRiaB?= NFTtfY1FVVOR NHLP[5RKdmS3Y3XzJHJQWyCycn;keYN1cW:wIIfpeIghTEiPRWG= MVyyOVA4Ojd3Mh?=
Huh7 M1fxXGZ2dmO2aX;uJGF{e2G7 MnLhOFAh|ryPIB?= NFfTOGgzPCCq MoOySG1UVw>? NH\q[m1KdmS3Y3XzJHJQWyCycn;keYN1cW:wIIfpeIghTEiPRWG= MUiyOVA4Ojd3Mh?=
Hep3B M4HBXGZ2dmO2aX;uJGF{e2G7 MYG0NEDPxE1i NUfHVGVxOjRiaB?= NU[1fYlMTE2VTx?= NHq4PVFKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= MojUNlUxPzJ5NUK=
Huh7 M4Dyd2Z2dmO2aX;uJGF{e2G7 M4jFVFQxKM7:TTC= M1qwcVI1KGh? NI\ndYtFVVOR M17ZXWlv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= M2DoRlI2ODd{N{Wy
SGC-7901 NEi5cHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnqXYw{OMLizszN M3ToW|Q5KGh? MoftSG1UVw>? M{LKUWJtd2OtIH;4ZYxqeGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NFqwTIMzPTd4N{C3Oi=>
COLO-800 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr1WZdKSzVyPUCuOFQyPjRizszN M{HIe3NCVkeHUh?=
EoL-1- M2TuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnwSJRiUUN3ME2wMlU3PDR4IN88US=> MVPTRW5ITVJ?
NCI-H209 M1zjcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDpPI5EUUN3ME2wMlkyPTV4IN88US=> MUHTRW5ITVJ?
ES1 NIntSlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HlRmlEPTB;MT6xNVQxQCEQvF2= MVzTRW5ITVJ?
NKM-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS0WI5VUUN3ME2xMlI2OzR5IN88US=> MlHwV2FPT0WU
NTERA-S-cl-D1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\RcmlEPTB;MT6zN|M1OSEQvF2= M2n2V3NCVkeHUh?=
MHH-ES-1 M1\xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPhTWM2OD1zLk[yNFY4KM7:TR?= MV3TRW5ITVJ?
ES8 NWDK[GJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzYTWM2OD1zLkeyOFE1KM7:TR?= NIDLfZNUSU6JRWK=
NCI-H720 MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXTTWM2OD1{LkKwOlk6KM7:TR?= M4ri[3NCVkeHUh?=
EW-3 NXP4eFNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW0c3lTUUN3ME2yMlI4PTN2IN88US=> NV7RXpZCW0GQR1XS
D-566MG MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImycnlKSzVyPUKuOFQ2PjhizszN NInURlFUSU6JRWK=
697 NILyZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJwOESxO|Mh|ryP MUnTRW5ITVJ?
ES5 Mk\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJwOEixPFkh|ryP NX7HV3hjW0GQR1XS
COLO-684 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrKTWM2OD1|LkWxOlk3KM7:TR?= MWTTRW5ITVJ?
ML-2 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNwNkCwOVgh|ryP NWS2c25bW0GQR1XS
MC-IXC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zrdmlEPTB;Mz62N|M6OyEQvF2= NEnrZlRUSU6JRWK=
DB M{fXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTTTWM2OD1|Lk[1OFQ5KM7:TR?= NH;iZ2VUSU6JRWK=
HCC2218 M4PONmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfTTWM2OD1|LkezNVA{KM7:TR?= NYLoUnl1W0GQR1XS
NCI-H510A NV3zeGI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVS3WJo6UUN3ME2zMlgzPzJ2IN88US=> M1m3eHNCVkeHUh?=
NCI-H526 M{DzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHBXnRKSzVyPUOuPFY6PThizszN M3H3SXNCVkeHUh?=
MV-4-11 M4i3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS0TWM2OD12LkGzN|M1KM7:TR?= MX3TRW5ITVJ?
PA-1 Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTRwMkWyPUDPxE1? M4DKbnNCVkeHUh?=
EW-22 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle0TWM2OD12LkO1PFYh|ryP M3zNfHNCVkeHUh?=
KASUMI-1 NFXuZ29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfCbnV2UUN3ME20MlQxOTB7IN88US=> MojyV2FPT0WU
LU-139 MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[5WIJKSzVyPUSuO|U5OjlizszN M37JWXNCVkeHUh?=
SBC-1 M3jiWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXiW|ZKSzVyPUSuPFA6ODhizszN NFfJVllUSU6JRWK=
H4 NF\ZUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfHbnJKSzVyPUSuPFk1PDNizszN M1PpOHNCVkeHUh?=
EW-11 NXPad2RIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfoTWM2OD13LkC4NFczKM7:TR?= MoXNV2FPT0WU
NBsusSR MnrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P3fWlEPTB;NT6xNlA2PSEQvF2= M4DyOHNCVkeHUh?=
RPMI-8226 NHnOVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTVwMUWyOFQh|ryP Mne3V2FPT0WU
DEL NFvCU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG3N4luUUN3ME21MlIxODB4IN88US=> NFPIcopUSU6JRWK=
ES4 NIjQdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTVwNUGzPFkh|ryP MoPDV2FPT0WU
GCT M1TIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf1ZVRoUUN3ME21MlU3QDV4IN88US=> Mo\tV2FPT0WU
NCI-H1048 M2j6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWwfXhDUUN3ME21Mlk4Ojd|IN88US=> MYLTRW5ITVJ?
NCI-SNU-1 NIDreGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe1eGFKSzVyPU[uNFIzKM7:TR?= Mn;RV2FPT0WU
ES7 NIjqVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmW0TWM2OD14LkCzOVc4KM7:TR?= M2DoeHNCVkeHUh?=
SW982 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLLZmNKUUN3ME22MlA6OTN5IN88US=> NV;GeGprW0GQR1XS
L-363 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDWbFlGUUN3ME22MlM{QTd2IN88US=> MU\TRW5ITVJ?
HT-1080 Mlm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWmzZYtyUUN3ME22MlQ6Pjh|IN88US=> Ml7IV2FPT0WU
HAL-01 NXP5dWtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{[1PWlEPTB;Nj61NVA6KM7:TR?= MnTFV2FPT0WU
NB14 MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTZwNkSwN|kh|ryP MUjTRW5ITVJ?
EW-13 NXy4cHdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDjU4VKSzVyPU[uO|c1OjRizszN MnzMV2FPT0WU
NY MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnOT2NHUUN3ME22Mlk1PjB3IN88US=> NGG0V4JUSU6JRWK=
NCI-SNU-5 Mo\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfwTWM2OD15LkGwOFM{KM7:TR?= M4\pPHNCVkeHUh?=
MS-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTdwMUe0PVQh|ryP MlLlV2FPT0WU
EW-16 NGX1WlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjrcGlnUUN3ME23MlMyQDZzIN88US=> NITFN2ZUSU6JRWK=
LU-65 NE\L[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHufZlKSzVyPUeuOFg1OTdizszN MYLTRW5ITVJ?
HGC-27 NYDob4xNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2wTWM2OD15LkeyNVc{KM7:TR?= NFPIfFNUSU6JRWK=
CTB-1 NFjCdpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DkZ2lEPTB;Nz63OlE4PSEQvF2= Mmj4V2FPT0WU
5637 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjxOlg4UUN3ME23MlkzQDZizszN M3XhVnNCVkeHUh?=
U251 M4\Hemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDiU5FKSzVyPUeuPVQxOTZizszN NEnTe2RUSU6JRWK=
HOS M1\VS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRThwMkOwNFch|ryP MmjoV2FPT0WU
DOHH-2 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfvTWM2OD16LkKzOVgh|ryP NVW0dWVtW0GQR1XS
EW-1 NVOxW4lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjXTWM2OD16LkOwNFg5KM7:TR?= NYHIdVQ2W0GQR1XS
BV-173 NVj4VWZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRThwNUW1OEDPxE1? MUXTRW5ITVJ?
8-MG-BA NH;YV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPNTWM2OD16Lk[4PVg5KM7:TR?= MWjTRW5ITVJ?
NB69 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PncmlEPTB;OD63NFkzOSEQvF2= NVjiWJpmW0GQR1XS
NCI-H69 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPoTWM2OD17LkmwPVYyKM7:TR?= NY\BR2dxW0GQR1XS
RS4-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHmNXJKSzVyPUGxMlIzODhizszN MnLBV2FPT0WU
ONS-76 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki3TWM2OD1zMT6yPVQ4KM7:TR?= MnezV2FPT0WU
SF539 NIrYVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnFe4VxUUN3ME2xNU41QDh7IN88US=> MkPyV2FPT0WU
HuO-3N1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHMTWM2OD1zMT61O|k3KM7:TR?= NU\1eolmW0GQR1XS
NCI-H1651 MmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13xfWlEPTB;MUKuN|EyPSEQvF2= NFy2fpBUSU6JRWK=
KARPAS-45 M1m5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTF{LkO3OkDPxE1? NGnoVHNUSU6JRWK=
SK-NEP-1 M37OXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT3[XdPUUN3ME2xNk41PjB7IN88US=> NG\oU4hUSU6JRWK=
LAMA-84 NX3i[Zh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfvTWM2OD1zMz6xNFk2KM7:TR?= NWf3[IpVW0GQR1XS
NCI-H1155 NYHYOI95T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfHNFFiUUN3ME2xN{4zQDV4IN88US=> NUTaWoVPW0GQR1XS
CTV-1 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF|LkS0OUDPxE1? M{iwcHNCVkeHUh?=
QIMR-WIL NIH0Z|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF|Lke4NVQh|ryP MYHTRW5ITVJ?
H9 NULp[FhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37XeGlEPTB;MUOuPFQ4PSEQvF2= NYDvd|VLW0GQR1XS
SK-MEL-1 NGrHV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEToOoVKSzVyPUGzMlk{PDdizszN MVHTRW5ITVJ?
HD-MY-Z MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe5b3JIUUN3ME2xOE4xPjN5IN88US=> MmC0V2FPT0WU
TI-73 NH\iTo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTF2LkKzOVYh|ryP NV;Ldo1sW0GQR1XS
JVM-3 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnq[4V2UUN3ME2xOU42PzF4IN88US=> MYfTRW5ITVJ?
D-247MG NH7MfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF3LkW5N{DPxE1? MkjhV2FPT0WU
VA-ES-BJ M1r3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF72W5pKSzVyPUG1MlYxQTdizszN MnL3V2FPT0WU
NOS-1 MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXTfJhKSzVyPUG1MlY2OjJizszN MXjTRW5ITVJ?
MOLT-4 NYfXRZJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF4Lke1NkDPxE1? M{jXenNCVkeHUh?=
Mo-T MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfkRmRKUUN3ME2xO{4xQDR7IN88US=> Mn3iV2FPT0WU
NCI-H1770 NF;IZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j1WGlEPTB;MUeuNVU1OyEQvF2= MYnTRW5ITVJ?
COLO-320-HSR MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTF5LkG4Nlch|ryP MmfhV2FPT0WU
TE-12 M3frS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzGSI1KSzVyPUG3MlcxPTRizszN NH\TOo9USU6JRWK=
NCI-H82 NW\iOHdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrkSW9LUUN3ME2xO{45PzJ6IN88US=> NWfTOXcyW0GQR1XS
NEC8 NVXmfFYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF6LkGzNVYh|ryP NXjSem1NW0GQR1XS
HSC-3 NFTMPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HmbWlEPTB;MUiuO|QyPCEQvF2= Ml\OV2FPT0WU
NCI-H1092 M2m3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTETWM2OD1zOD63OVk2KM7:TR?= M{PnfXNCVkeHUh?=
NCI-H292 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTF7LkC0PFkh|ryP MWnTRW5ITVJ?
L-428 MkHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz3TWM2OD1zOT61OVkh|ryP NUTXUHJmW0GQR1XS
LU-134-A NWW1WHd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3GeIRKSzVyPUG5MlU4OiEQvF2= M{P3S3NCVkeHUh?=
GI-ME-N M{jJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoT5TWM2OD1zOT61O|Q4KM7:TR?= NFLl[FRUSU6JRWK=
ALL-PO NV3lNIZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzoTWM2OD1zOT61PVczKM7:TR?= MknFV2FPT0WU
D-283MED Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrFb254UUN3ME2xPU46OTVizszN NF\5eVFUSU6JRWK=
D-423MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF7Lkm5Olch|ryP MoXXV2FPT0WU
CAKI-1 NFvtXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jTdWlEPTB;MkCuNlIyQSEQvF2= NHzOSpJUSU6JRWK=
ETK-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XTSmlEPTB;MkCuNlYyPSEQvF2= NYnaWHZFW0GQR1XS
G-402 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7YfIN7UUN3ME2yNE42OzN2IN88US=> NHjETnZUSU6JRWK=
HL-60 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\mXGlEPTB;MkGuNVYyOyEQvF2= Mle1V2FPT0WU
A2058 MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYD1SpAzUUN3ME2yNU41PDd5IN88US=> MUfTRW5ITVJ?
CHP-212 M3fCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKwTWM2OD1{MT65NFUyKM7:TR?= M3ThbXNCVkeHUh?=
KY821 MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorMTWM2OD1{MT65O|Uh|ryP MW\TRW5ITVJ?
TYK-nu NVvYXJlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUCxZYV[UUN3ME2yNk4xPjVzIN88US=> M4D1ZXNCVkeHUh?=
JVM-2 MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXFTWM2OD1{Mj6yPVg{KM7:TR?= MnfMV2FPT0WU
KU812 MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJ{LkezNVIh|ryP Ml3oV2FPT0WU
MKN28 NGjicFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[zfWlEPTB;MkKuPVAyPSEQvF2= MWDTRW5ITVJ?
ECC10 MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlK4TWM2OD1{Mz63OFEh|ryP NGjwN4ZUSU6JRWK=
BHT-101 NXvsb|N[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHES2JKSzVyPUK0MlAxODhizszN NWHwU28{W0GQR1XS
DU-4475 Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJ2LkOzN|ch|ryP MWnTRW5ITVJ?
769-P M2fL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJ2Lki0OlYh|ryP MYfTRW5ITVJ?
HEC-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;GSWlEPTB;MkWuOFQ2KM7:TR?= NEi5NXdUSU6JRWK=
MOLT-13 M3L2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWm4dI41UUN3ME2yOU42OzNzIN88US=> MWrTRW5ITVJ?
8505C MlzPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zrWGlEPTB;Mk[uOFk4PyEQvF2= NHftd2VUSU6JRWK=
GB-1 NV;HUlBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJ4LkexO|Yh|ryP M2\J[HNCVkeHUh?=
SF126 NH;5dG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[5flhZUUN3ME2yOk44PjR6IN88US=> NInYT2RUSU6JRWK=
A4-Fuk NFO0[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzVfHZKSzVyPUK3MlEzPzFizszN Mmn5V2FPT0WU
OVCAR-8 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHITWM2OD1{Nz6xOVM6KM7:TR?= MVzTRW5ITVJ?
NCI-H1304 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HOTmlEPTB;MkeuOVQh|ryP NYTONXZlW0GQR1XS
GR-ST MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jRVmlEPTB;MkiuNFQ4KM7:TR?= NVLMdWhGW0GQR1XS
G-401 M4fWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILNTnhKSzVyPUK4MlUxQTZizszN M1LvfXNCVkeHUh?=
LXF-289 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnjRmxKUUN3ME2yPE42PjVzIN88US=> MoTCV2FPT0WU
DBTRG-05MG NFjSXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTRTWM2OD1{OD65NlA1KM7:TR?= M4G5dHNCVkeHUh?=
YKG-1 NITjTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TFcmlEPTB;MkmuPFY5KM7:TR?= NH3oWFZUSU6JRWK=
GAMG NX3SSIY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ7Lkm5N{DPxE1? MU\TRW5ITVJ?
HCT-116 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnSTWM2OD1|MD6wOVQ5KM7:TR?= MkPOV2FPT0WU
S-117 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofqTWM2OD1|MT6yNlU4KM7:TR?= MoD4V2FPT0WU
NCI-H1693 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\JTWM2OD1|Mz62OVQzKM7:TR?= MnvBV2FPT0WU
A427 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTN|Lkm5O|Yh|ryP MkPqV2FPT0WU
HT-29 MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV33Zm1QUUN3ME2zOE43ODN{IN88US=> NWqwbZlrW0GQR1XS
P12-ICHIKAWA M4DYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV70WZRoUUN3ME2zOE44PDlzIN88US=> NFPaVJJUSU6JRWK=
CAL-51 NXTUc4ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWmxRVV6UUN3ME2zOU4xPzB7IN88US=> MlXNV2FPT0WU
Ramos-2G6-4C10 NXnuVG1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN3LkK0NlUh|ryP NFL3UnBUSU6JRWK=
SCH MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXXOmE2UUN3ME2zOk41OTd2IN88US=> MnrxV2FPT0WU
SK-MEL-24 NE[xZnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTN4LkmwOFQh|ryP MYTTRW5ITVJ?
SW1573 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIewcpJKSzVyPUO4MlczOTZizszN M3\aeXNCVkeHUh?=
BALL-1 MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzYTWM2OD1|OT6yNVI6KM7:TR?= MWLTRW5ITVJ?
BE-13 NWDL[GhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTN7LkOyPUDPxE1? M37ufXNCVkeHUh?=
GI-1 M13WbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2CyXmlEPTB;M{muPFY1PyEQvF2= NVzjSoNMW0GQR1XS
GOTO MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTN7LkmxN|kh|ryP MkjwV2FPT0WU
A673 NGn4UpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW1U2NyUUN3ME20NU4xOzR|IN88US=> MmD1V2FPT0WU
KG-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzCVohmUUN3ME20N{4{QTRizszN Mn\rV2FPT0WU
GP5d NEXITmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfXTWM2OD12ND6wOlY3KM7:TR?= MmPvV2FPT0WU
MFM-223 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jlOGlEPTB;NESuNVIzQCEQvF2= MV3TRW5ITVJ?
OAW-42 NYfaR2ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\5TWM2OD12ND6yOlQ{KM7:TR?= MnrHV2FPT0WU
C8166 Mkm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTR3LkC4NlIh|ryP M4\0dXNCVkeHUh?=
LU-99A NVfJ[mg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGToW21KSzVyPUS2MlE{OjJizszN MkDWV2FPT0WU
NCI-H23 NXft[ZQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXtTWM2OD12Nj6xO|g2KM7:TR?= NWDkU2xmW0GQR1XS
HO-1-N-1 M{fE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{njWGlEPTB;NEeuNFk6QCEQvF2= MXHTRW5ITVJ?
A3-KAW MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TBVWlEPTB;NEeuNVAxPyEQvF2= NVTHPIJ5W0GQR1XS
CGTH-W-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPVNHBKSzVyPUS3MlUxPjlizszN MUjTRW5ITVJ?
DJM-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTR5LkW0NVMh|ryP NEjRW4xUSU6JRWK=
A101D NGTEZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[wVFdjUUN3ME20O{43OzV5IN88US=> M1jk[XNCVkeHUh?=
BB30-HNC NILBZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHSeYhKSzVyPUS4MlMxPzJizszN M1;pfnNCVkeHUh?=
T98G MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPDW4NKSzVyPUS4MlQ3OzNizszN MVHTRW5ITVJ?
NCI-H1573 M4L3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXraRlc3UUN3ME20PU41PDZ{IN88US=> MoDEV2FPT0WU
MEG-01 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELtUIJKSzVyPUS5Mlc1OTFizszN NV7ZXG1mW0GQR1XS
WM-115 MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;1S3lIUUN3ME20PU46OjJ{IN88US=> M3;vT3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western Blot
DR5/CHOP; 

PubMed: 25531448     


(A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5.

γH2AX/H2AX; 

PubMed: 22933245     


FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX.

pATM; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

53BP1; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

NF-kB; 

PubMed: 27686740     


(C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 

pS6/S6; 

PubMed: 24831086     


HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies. 

25531448 22933245 27686740 24831086
Immunofluorescence
DNA damage; 

PubMed: 27686740     


(A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX).

γH2AX; 

PubMed: 28069876     


Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.

27686740 28069876
Growth inhibition assay
Cell viability ; 

PubMed: 25531448     


A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.

25531448
ELISA
IL-8; 

PubMed: 28456021     


ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. 

GLP-1; 

PubMed: 29392078     


Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.

28456021 29392078
In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

- Collapse

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

- Collapse
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04024254 Not yet recruiting Drug: Folic Acid Tablet Ovarian Cancer|Breast Cancer|Folic Acid Deficiency Rush University Medical Center August 2019 Phase 2|Phase 3
NCT04005690 Recruiting Drug: Cobimetinib|Drug: Olaparib Resectable Pancreatic Ductal Adenocarcinoma|Stage 0 Pancreatic Cancer AJCC v8|Stage I Pancreatic Cancer AJCC v8|Stage IA Pancreatic Cancer AJCC v8|Stage IB Pancreatic Cancer AJCC v8|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8 OHSU Knight Cancer Institute|National Cancer Institute (NCI) August 1 2019 Phase 2
NCT03786796 Recruiting Drug: Olaparib Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma|Kidney Cancer|Renal Carcinoma|Kidney Cancer Metastatic Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|AstraZeneca June 3 2019 Phase 2
NCT03745950 Not yet recruiting Drug: Olaparib Oral Capsule|Drug: Placebo oral capsule Endometrial Carcinoma ARCAGY/ GINECO GROUP February 1 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to prepare the solution of the compound (S1060) for in vivo study?

  • Answer:

    We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.

  • Question 2:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 3:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID